VRTX logo

Vertex Pharmaceuticals Incorporated (VRTX)

$515.02

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on VRTX

Market cap

$130.58B

EPS

15.53

P/E ratio

29.7

Price to sales

10.27

Dividend yield

--

Beta

0.281262

Price on VRTX

Previous close

$520.66

Today's open

$529.94

Day's range

$513.80 - $531.37

52 week range

$412.27 - $568.67

Profile about VRTX

CEO

Reshma Kewalramani

Employees

6400

Headquarters

Boston, MA

Exchange

Nasdaq Global Select

Shares outstanding

253537674

Issue type

Common Stock

VRTX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on VRTX

Vertex Pharmaceuticals: Look For Povetacicept Approval In 2 Weeks As Next Catalyst

Vertex Pharmaceuticals Incorporated remains a Buy: shares look fairly valued, but durable CF cash flows and pipeline potential support long-term market outperformance. VRTX's CF franchise accounts for an estimated 60% of market value, with high-single-digit growth and patent protection supporting a decade of cash generation. Journavx offers the strongest approved non-CF opportunity, with growing prescriptions and off-label demand offsetting pricing headwinds and chronic-pain trial risk.

news source

Seeking Alpha • Nov 20, 2026

news preview

2 Growth Stocks to Buy in November Without Any Hesitation

Vertex Pharmaceuticals' core business remains healthy, and it has a portfolio of kidney disease candidates that could top $10 billion in annual sales. Regeneron's Dupixent looks unstoppable, while a newer formulation of Eylea cushions the decline of the older version.

news source

The Motley Fool • Nov 19, 2026

news preview

Worried investors are paying up for these stocks — some with up to 49% upside, analysts say

Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.

news source

Market Watch • Nov 18, 2026

news preview

Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loom

Vertex Pharmaceuticals NASDAQ: VRTX is approaching a Nov. 30 U.S. regulatory decision for its kidney disease drug povetacicept, with a series of clinical readouts expected through 2027 as the company seeks to expand beyond its cystic fibrosis business.

news source

MarketBeat • Nov 17, 2026

news preview

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Johnson & Johnson offers a diversified healthcare portfolio and massive scale across its MedTech and pharmaceutical segments. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while expanding into high-growth gene therapies.

news source

The Motley Fool • Nov 17, 2026

news preview

Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom

Vertex Pharmaceuticals NASDAQ: VRTX is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic pain and other conditions, company executives said at a UBS investor event.

news source

MarketBeat • Nov 16, 2026

news preview

Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 16, 2026

news preview

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into gene editing and pain management.

news source

The Motley Fool • Nov 13, 2026

news preview

Impax Small Cap Fund Q3 2026 Portfolio Review

The portfolio outperformed the Russell 2000 Index in what was a difficult period for the small cap asset class. Financials was the largest contributing sector, almost entirely due to stock selection. Top contributors include Victory Capital and Acadian Asset Management.

news source

Seeking Alpha • Nov 12, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Vertex Pharmaceuticals Incorporated

Open an M1 investment account to buy and sell Vertex Pharmaceuticals Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in VRTX on M1